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ABSTRACT 30 
In late pregnancy, maternal insulin resistance occurs to support fetal growth but little is 31 
known about insulin-glucose dynamics close to delivery. This study measured insulin 32 
sensitivity in mice in late pregnancy, day (D) 16, and near term, D19, (term 20.5D). Non-33 
pregnant (NP) and pregnant mice were assessed for metabolite and hormone concentrations, 34 
body composition by dual energy X-ray absorptiometry, tissue insulin signalling protein 35 
abundance by Western blotting, glucose tolerance and utilisation, and insulin sensitivity using 36 
acute insulin administration and hyperinsulinaemic-euglycaemic clamps with 3H-glucose 37 
infusion. Whole body insulin resistance occurred in D16 pregnant dams in association with 38 
basal hyperinsulinaemia, insulin-resistant endogenous glucose production and 39 
downregulation of several proteins in hepatic and skeletal muscle insulin signalling pathways 40 
relative to NP and D19 values. Insulin resistance was less pronounced at D19 with restoration 41 
of NP insulin concentrations, improved hepatic insulin sensitivity and increased abundance of 42 
hepatic insulin signalling proteins. At D16, insulin resistance at whole body, tissue and 43 
molecular levels will favour fetal glucose acquisition while improved D19 hepatic insulin 44 
sensitivity will conserve glucose for maternal use in anticipation of lactation.  Tissue 45 
sensitivity to insulin, therefore, alters differentially with proximity to delivery in pregnant 46 
mice with implications for human and other species.  47 
 48 
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 54 
 55 
 56 
 57 
INTRODUCTION 58 
During pregnancy, maternal metabolism adapts to support offspring growth. In particular, 59 
there are changes in insulin sensitivity, which affects the availability and fate of nutrients in 60 
both mother and conceptus (1,2). The specific adaptations depend on the stage of pregnancy 61 
as metabolic demands increase with expansion of the gravid uterus (3,4). In humans and rats, 62 
early pregnancy is a period of lipid accumulation and unchanged or increased insulin 63 
sensitivity, whereas, later pregnancy is characterised by lipid mobilisation and insulin 64 
resistance, common features of overt Type 2 diabetes (1,2,5,6). Indeed, whole body resistance 65 
to the hypoglycaemic action of insulin has been reported during late pregnancy in a wide 66 
range of species including rabbits, dogs, sheep, horses as well as rats and humans (7-13). It is 67 
often accompanied by reduced maternal glucose utilisation, particularly in skeletal muscle, 68 
although there is less consensus about the actions of insulin on hepatic glucogenesis during 69 
pregnancy (10,12,14,15). Most studies of insulin sensitivity during late pregnancy have been 70 
carried out between 60-85% of gestation with few measurements closer to term when fetal 71 
nutrient demands are maximal yet maternal nutrient requirements may also be changing in 72 
preparation for the imminent onset of labour and lactation. 73 
 74 
Total conceptus mass varies not only with increasing gestational age but also between species 75 
both in total and as a percentage of maternal mass (16).  Fetal growth rate is high during late 76 
mouse pregnancy and results in the gravid uterus accounting for 30% of maternal mass at 77 
term (16).    This is a higher percentage than found in monotocous species like humans and 78 
sheep (5-9%) or the values of 12-25% seen in other polytocous animals like dogs, pigs and 79 
rats (16). Despite this, little is known about insulin sensitivity in pregnant mice, even though 80 
they are used widely in genetic and developmental studies in which variations in maternal 81 
insulin sensitivity may affect the ensuing offspring phenotype (17,18). The molecular basis of 82 
insulin resistance during late pregnancy is also still poorly understood in many species. 83 
Tissue insulin receptor (IR) abundance appears to be unaffected by pregnancy, although there 84 
is evidence for defects in the early stages of insulin signal transduction downstream of the IR 85 
in skeletal muscle of both rats in late pregnancy and pregnant women insulin resistant due to 86 
obesity or gestational diabetes (19-23).  Hence, the aims of this study were to measure 87 
glucose-insulin dynamics, whole body insulin sensitivity and tissue insulin signalling proteins 88 
in non-pregnant (NP) mice and in pregnant dams in late gestation and close to term. C57B1/6 89 
mice was used in the study because this strain has been used extensively to investigate the 90 
genetic and environmental regulation of feto-placental development (17,24).  91 
   92 
 93 
MATERIALS AND METHODS 94 
 95 
Animals  96 
C57Bl/6 females (n=123) were group housed at 21ºC under 12hr dark:12hr light conditions 97 
with free access to water and food (RM3, Special Diet Services). Aged 8-12 weeks, females 98 
were time mated with C57Bl/6 males with the presence of a copulatory plug defined as day 99 
(D)1 of a D20.5 pregnancy. Pregnant (n=77) and remaining non-pregnant (NP, n=46) mice 100 
were weighed every five days while food intake was measured every three days. Mice were 101 
allocated to one of the following procedures: 1) tissue and blood collection (n=30), (2) dual 102 
energy X-ray absorptiometry (DEXA, n=29) scanning, (3) glucose tolerance tests (GTT, 103 
n=28) or insulin tolerance tests (ITT, n=20) or (4) a hyperinsulinaemic-euglycaemic clamp 104 
(HEC) together with D-3H-glucose and 2-deoxyglucose (2DG) administration (n=18). All 105 
experiments were carried under the UK Animals (Scientific Procedures) Act 1986 after 106 
ethical review by the University of Cambridge.   107 
 108 
 109 
Experimental procedures 110 
Tissue and blood collection 111 
Between 08.00-10.00 h in fed conditions, pregnant dams at D16 and D19 and age-matched 112 
NP females (n=10 mice per group) were weighed and anaesthetised (10 µl/g of fentanyl-113 
fluanisone: midazolam in sterile water, 1:1:2, Jansen Animal Health, ip). A cardiac blood 114 
sample was taken before euthanasia by cervical dislocation. In NP mice, liver, heart, kidneys, 115 
skeletal muscle (biceps femoris) and retroperitoneal fat were dissected, weighed and snap 116 
frozen in liquid nitrogen. In pregnant dams, the gravid uterus, hysterectomised carcass and 117 
individual fetuses and placentas were weighed before maternal tissue collection. Blood 118 
glucose concentrations were measured on a hand held glucometer (One Touch Ultra, 119 
LifeScan, UK). After centrifugation, the plasma was stored at -20˚C to measure metabolite 120 
and hormone concentrations.  121 
 122 
DEXA scanning 123 
Whole body fat and lean mass content were determined by DEXA scanning (Lunar PIXImus 124 
densitometer; GE lunar Corp., Madison WI) in intact NP females (n=10) and hysterectomised 125 
pregnant mice killed by cervical dislocation between 08.00-10.00 h (D16 n=7, D19 n=10). 126 
Values were expressed as a proportion of total body weight in NP mice and of 127 
hysterectomised weight in pregnant dams. 128 
 129 
Glucose tolerance test and insulin tolerance test  130 
Conscious NP and pregnant mice received either a GTT (NP n=11, D16, n=9, D19 n-8) or 131 
ITT (n=6-8 mice per group) after fasting from 08.00 h for 6 h or 3.5 h, respectively. Blood 132 
samples (≤ 5µl) were taken from the tail vein immediately before intraperitoneal 133 
administration of either glucose (10% w/v, 1 g/kg body weight) or insulin (0.25 U/kg, human 134 
insulin, Actrapid, Novo Nordisk) and, thereafter, at 15 to 30 min intervals for 120 min to 135 
measure blood glucose concentrations as above. The mice were then killed by cervical 136 
dislocation. 137 
 138 
Hyperinsulinaemic-euglycaemic clamp  139 
The HEC was performed as described previously (25). Briefly, NP and pregnant mice fasted 140 
for 2.5 h (NP n=7, D16, n=5, D19 n=6) were anaesthetised with a mixture of ventranquil: 141 
dormicum: fentanyl (1:2:10 in 3 units of water, 10 μl/g body weight, ip, Janssen-Cilag, 142 
Tilburg, Netherlands) and maintained at 37ºC using a servo-controlled thermopad (Harvard 143 
Instruments, UK). After catheterising a tail vein, D-3H-glucose was infused continuously 144 
(0.006MBq/min in PBS, 50µl/hr, iv, 370-740GBq/mmol Perkin Elmer, UK). After steady 145 
state was achieved at 60 min (basal state, ≈ 3.5 h fasted), two blood samples (≤ 50µl each) 146 
were taken 10 min apart from the tail. Insulin was then injected as a bolus (3.3 mU, iv, 147 
Actrapid, human insulin, Novo Nordisk) followed by infusion (0.09 mU/min) together with 148 
the D-3H-glucose. Blood glucose levels was monitored every 5 min for the first 20 min after 149 
insulin administration and then at 10 min intervals until the end of the protocol (≤ 5 µl per 150 
sample). When a decrease in blood glucose concentration was detected 5-10 min after 151 
beginning the insulin infusion, a variable rate glucose infusion (12.5% w/v PBS, Sigma, iv) 152 
was begun and adjusted every 5-10 min thereafter to maintain blood glucose concentrations 153 
at mean basal levels. At 50 min after insulin infusion, 2-deoxy-glucose (14C-2DG, specific 154 
activity: 9.25-13.0GBq/mmol, Perkin Elmer, UK) was injected intravenously. By 70 min of 155 
insulin administration, blood glucose levels were clamped at basal concentrations and a 156 
further three blood samples (≤ 50µl each) were collected from the tail at 10 min intervals. 157 
The mice were then killed by cervical dislocation and samples of biceps femoris and 158 
retroperitoneal fat were collected from all animals together with the fetus and placenta 159 
adjacent to the cervix in each horn (n=2 fetuses and placentas per litter) for analysis of tissue 160 
14C-2DG content. The rates of glucose utilization and production in basal and 161 
hyperglycaemic states together with whole body and hepatic sensitivity to insulin were 162 
calculated as described previously (25,26).  163 
 164 
 165 
Biochemical analyses 166 
 167 
Hormone and metabolite concentrations 168 
Plasma D-3H-glucose concentrations were measured by scintillation counting (Hidex 300SL, 169 
LabLogic Ltd, Sheffield, UK), after samples were deproteinised with 20% trichloric acid and 170 
dried to eliminate tritiated water. Plasma leptin and insulin concentrations in the fed state 171 
were measured simultaneously using a 2-plex specific immunoassay (Meso Scale Discovery). 172 
The inter-assay coefficients of variation (CV) were 10.8% and 9.7%, respectively. Plasma 173 
insulin concentrations during the HEC were measured by ELISA (Crystal Chem Inc., 90090), 174 
which detected both murine and human insulin. The inter-assay CV was ≤ 10%. Plasma IGF1 175 
levels were also measured by ELISA (ImmunoDiagnostic Systems) with an inter-assay CV of 176 
4.6%.  Enzymatic assay kits were used to determine the plasma concentrations of 177 
triglycerides (TG), total cholesterol (Siemens Healthcare, CV 5.5% and 4.9% respectively) 178 
and free fatty acids (Roche, CV 4.5%).   179 
 180 
Tissue biochemical composition  181 
Hepatic glycogen content was measured enzymatically, using amyloglucosidase as reported 182 
previously (27).  The total fat content of the liver and pooled samples of skeletal muscle were 183 
measured using the modified Folch method (28). To determine tissue phosphorylated 2DG 184 
(p2DG) content, tissues were homogenised in 0.5% perochloric acid and the homogenates 185 
neutralised to separate p2DG from 2DG by precipitation, as described previously (29). 186 
 187 
 188 
Protein expression in insulin signalling and lipid metabolism pathways 189 
Proteins were extracted (~100 mg, NP n=10, D16 n=5, D19 n=5-6) from the liver and 190 
skeletal muscle and quantified using Western blotting as described previously [30]. 191 
Successful transfer and equal protein loading was confirmed by Ponceau-S staining of 192 
membranes before incubation with antibody (Table 1). Protein abundance was determined by 193 
measuring pixel intensity of the protein bands using ImageJ analysis software (U.S. National 194 
Institutes of Health, Bethesda, MD, USA).  195 
 196 
Statistics 197 
All statistical analyses and calculations were performed on the GraphPad Prism 4.0. For most 198 
of the data, differences between NP, D16 and D19 animals were analysed by one way 199 
analysis of variance (ANOVA) with Bonferroni post hoc test. When the ANOVA indicated 200 
an effect of pregnancy, differences between D16 and D19 of pregnancy were assessed 201 
separately by unpaired t-test. Changes within the same group were assessed by paired t-test or 202 
by t-test the mean change differing from zero. For GTT and ITT protocols, the changes in 203 
glucose concentration were analysed by two-way ANOVA with time as a repeated measure. 204 
The area above the curve (AAC) in the GTT and area under the curve (AUC) in the ITT for 205 
the changes in glucose concentrations were calculated using the trapezoid rule. Fetal and 206 
placental data were averaged for each litter before calculation of mean values at each 207 
gestational age.  208 
 209 
 210 
RESULTS  211 
 212 
Biometry 213 
Pregnant dams were heavier than NP females due to the gravid uterus and increased weights 214 
of several maternal tissues, although, when weights were expressed as a percentage of total or 215 
hysterectomised body weight, only the liver and retroperitoneal fat pads were proportionately 216 
heavier during pregnancy (Table 2). However, DEXA scanning showed that no significant 217 
changes in body fat content during pregnancy (Table 2). As expected [31], the gravid uterus 218 
and individual fetuses weighed less while the placentas weighed more at D16 than D19 with 219 
no difference in litter size between the two groups (Table 2). Hepatic fat and glycogen 220 
content were higher in total during pregnancy in line with the increased tissue weight but not 221 
when expressed per mg tissue (Table 2). Skeletal muscle fat content of pooled samples 222 
appeared to be greater in pregnant than NP animals when expressed per mg tissue (Table 2). 223 
Pregnant dams increased their food intake relative to NP females from D9 of pregnancy (data 224 
not shown). 225 
 226 
Metabolites and hormones concentrations 227 
Blood glucose concentrations were unaffected by pregnancy in the fed state but were 228 
significantly lower than NP values in both pregnant groups after 3.5 h of fasting (Table 3). At 229 
6 h of fasting, blood glucose levels were similar to those seen at 3.5 h of fasting in NP and 230 
D19 groups but were significantly higher than at 3.5 h of fasting in D16 dams (Table 3). In 231 
fed animals, plasma FFA concentrations were significantly lower in both pregnant groups 232 
than in NP females with the lowest values in D16 dams (Table 3). Cholesterol concentrations 233 
were also significantly lower during pregnancy and declined significantly between D16 and 234 
D19 (Table 3). Insulin concentrations were significantly higher in D16 dams than NP females 235 
with intermediate values in D19 dams (Table 3). Plasma leptin concentrations were higher 236 
while plasma IGF1 levels were lower in pregnant than NP groups, with no significant 237 
differences with gestational age (Table 3).  238 
 239 
Glucose tolerance 240 
The increment in blood glucose concentrations, the time course of the concentration changes 241 
and the AUC did not differ with pregnancy or gestational age (Figure 1A).  Blood glucose 242 
concentrations remained elevated for the entire 120 min after glucose injection in all 3 groups 243 
(Figure 1B).  244 
 245 
Insulin sensitivity 246 
Blood glucose concentrations were significantly lower than baseline 15 min after acute 247 
insulin injection in all 3 groups and remained depressed for up to 120 min (Figure 1B). 248 
However, the decrement in blood glucose concentrations was greater in NP than both 249 
pregnant groups from 15-90 min after insulin injection (Figure 1B). In D16 dams, blood 250 
glucose level returned to baseline by 60 min and were significantly greater than baseline 120 251 
min after insulin injection (Figure 1B). The AAC also differed significantly with pregnancy 252 
and gestational age, and indicated that pregnant dams were less sensitive to insulin than NP 253 
females, particularly at D16 (Figure 1B).  254 
 255 
Whole body and hepatic insulin sensitivity were investigated in more detail by HEC coupled 256 
with 3H-glucose infusion. In all 3 groups, blood glucose levels were clamped at basal, 257 
euglycaemic levels by 70-90 min after beginning insulin infusion (Figure 2A). At this time, 258 
plasma insulin concentrations were within the post-prandial range and 5-6 fold higher than 259 
the basal values in all 3 groups (Figure 2B). However, steady-state insulin concentrations 260 
during the clamp were significantly lower in the D19 than NP or D16 groups (Figure 2B).  261 
Whole body insulin sensitivity, measured as GIR, was lower in D16 dams than in the other 262 
two groups and similar in NP and D19 pregnant groups (Figure 2C).  The findings were 263 
identical when GIR was adjusted for the differences in the increment in insulin concentration 264 
during the clamp period (data not shown).  Whole body insulin sensitivity was also calculated 265 
as the difference between glucose utilisation in hyperinsulinaemic (Rd) and basal states (Ra). 266 
This difference varied widely between individuals, particularly in D16 dams, and was only a 267 
significant increment in NP females, indicative of insulin resistance in both D16 and D19 268 
dams (Figure 2D).  During hyperinsulinaemia, EGP continued at a significant rate in all 3 269 
groups (p<0.02, greater than zero, all groups, t-test) and occurred at the highest rate in D16 270 
dams (Figure 2D).  Hepatic insulin sensitivity, calculated as a significant difference in 271 
glucose production between basal and hyperinsulinaemic states, was only detected in D19 272 
dams and was greater in absolute value at D19 than D16 (Figure 2D).   273 
 274 
Whole body and tissue glucose utilisation 275 
Whole body glucose utilization was significantly greater in D19 dams than NP females in 276 
basal conditions (Ra) while, during hyperinsulinaemia (Rd), it was higher in D16 dams than 277 
NP females with intermediate values in D19 dams (Figure 2C). Tissue glucose utilization 278 
during hyperinsulinaemia, measured as p2DG content, in skeletal muscle and adipose tissue 279 
varied widely, particularly in NP females, but was not significantly different between 280 
pregnant and NP animals nor between D16 and D19 dams (Table 4). Fetal p2DG content was 281 
similar to that of maternal tissues at both ages (Table 4). Placental p2DG content was 282 
significantly higher than in the fetus or maternal tissues at D19, but not at D16 (Table 4).  283 
 284 
 285 
 286 
Tissue insulin-IGF signalling and lipid metabolism 287 
Hepatic insulin-IGF signalling pathway was largely downregulated in D16 dams compared 288 
with NP females (InsR, IGF1R, pAkt-T308, pMAPK, Figure 3A). In contrast, at D19, the 289 
insulin signalling pathway was largely upregulated, compared to NP and D16 pregnant 290 
groups (IGF1R, total Akt, pAkt-S473, total Gsk3, pGsk3, total S6K, total MAPK and 291 
pMAPK, Figure 3A). Pregnancy had less effect on insulin signalling pathways in skeletal 292 
muscle with increased abundance of p85α at D16 and of pAkt T308 and total MAPK at D19 293 
compared to NP values and decreased total Akt and pS6K abundance at D19 compared to 294 
either NP or D16 values (Figure 3B).  295 
 296 
Hepatic abundance of lipogenic SREBP was reduced at D16 but normalised by D19 while 297 
PPARα, PPARγ and LPL were reduced in both pregnant groups relative to NP values (Figure 298 
3C). Hepatic abundance of PPARγ and LPL was significantly lower in D19 than D16 dams 299 
(Figure 3D). Hepatic FATP1 was lower in D19 dams than NP females (Figure 3C).In skeletal 300 
muscle, SREBP was reduced in D16 but not D19 dams while PPARγ and LPL abundance 301 
were lower in both pregnant groups relative to NP values (Figure 3D).  Skeletal muscle 302 
expression of LPL was greater and FATP1 was less at D16 than D19 (Figure 3D). 303 
 304 
 305 
DISCUSSION 306 
 307 
This is the first study to measure insulin sensitivity of glucose metabolism in pregnant mice 308 
and shows significant changes in insulin-glucose dynamics with both pregnancy and 309 
gestational age over the last 20% of gestation. In particular, there were changes in insulin 310 
concentration, glucose utilization and production, and in whole body and tissue insulin 311 
sensitivity between D16 and D19 of pregnancy. Protein abundance in the hepatic and skeletal 312 
muscle insulin signalling pathways also differed during pregnancy in line with the gestational 313 
changes in insulin sensitivity and glucose metabolism. Overall, insulin resistance and EGP 314 
capacity were more pronounced at D16 than D19, which indicates that mice adapt their 315 
metabolic strategy for supporting pregnancy as delivery approaches. There were also changes 316 
in body composition, tissue lipogenic signalling proteins and circulating concentrations of 317 
leptin and IGFI during pregnancy which indicate that, like other species (2,5), mice 318 
accumulate fat in specific deposits during early but not late pregnancy and are resistant to the 319 
actions of leptin, as well as insulin, in late pregnancy, when their food intake increases 320 
despite hyperleptinaemia.  321 
 322 
While glucose tolerance was unaffected by pregnancy, insulin resistance was evident in D16 323 
pregnant mice. These dams were hyperinsulinaemic in both fed and fasted states, had a 324 
significantly smaller hypoglycaemic response to acute insulin administration and required 80-325 
85% less exogenous glucose to maintain euglycaemia during the HEC than the other two 326 
groups of animals.  This decrement in GIR from NP values was greater than seen in rats, dogs 327 
and women at an equivalent stage of pregnancy (7,9,12).  In addition, insulin failed to inhibit 328 
EGP in D16 mouse dams. Similar findings have been made in pregnant rats but, in women, 329 
rabbits and dogs with a proportionately smaller gravid uterus, insulin continues to reduce 330 
EGP during late pregnancy, although not always as effectively as in the NP state 331 
(9,10,12,14,15). Furthermore, whole body glucose utilisation varied widely and did not 332 
increase significantly during hyperinsulinaemia in D16 pregnant mice, unlike the significant 333 
increment seen in NP females. Although there were no significant changes in tissue p2DG 334 
content, skeletal muscle expression of p85α, a known regulator of human muscle insulin 335 
resistance (32), was increased while hepatic expression of IR and several downstream insulin 336 
signalling proteins were decreased in D16 mouse dams, consistent with their reduced whole 337 
body and liver insulin sensitivity.  Collectively, these findings indicate that insulin resistance 338 
occurs at whole body, tissue and molecular levels at D16 of mouse pregnancy.  339 
 340 
By D19, insulin concentrations in fed and fasted states had returned to NP levels and the 341 
hypoglycaemic response to acute insulin administration was greater than at D16, although 342 
still less than in NP females. Insulin concentrations were also lower during the clamp in D19 343 
dams which suggests increased insulin clearance consistent with findings in dogs during late 344 
pregnancy (12). A degree of hepatic insulin sensitivity was restored in D19 pregnant mice as 345 
insulin infusion now reduced EGP. Hepatic expression of several proteins in the insulin 346 
signalling pathway were also up-regulated at D19 relative to the other two groups. Improved 347 
hepatic insulin signalling at D19 is also suggested by normalised expression of the insulin-348 
regulated transcription factor, SREBP (33). Furthermore, the GIR required to maintain 349 
euglycamia during hyperinsulinaemia was significantly greater at D19 than D16, indicative of 350 
improved whole body insulin sensitivity near term. However, tissue p2DG content showed no 351 
change between D16 and D19, and whole body glucose utilisation was unresponsive to 352 
insulin at D19, which suggests that a degree of insulin resistance still persists in pregnant 353 
mice close to delivery. These apparent contradictions probably reflect the non-insulin 354 
dependent, transplacental flux of glucose, which would increase GIR and lead to 355 
overestimation of the actual maternal insulin sensitivity, particularly when fetal glucose 356 
demands are high near term (2,34).  Insulin sensitivity, therefore, appears to change 357 
differentially in individual maternal tissues with proximity to delivery in pregnant mice. 358 
 359 
In basal conditions, the rate of endogenous glucose production (Ra) in the NP females fasted 360 
for 3.5hr in the present study was higher than that seen previously in older male mice fasted 361 
overnight (25).  Insulin also had little effect on the rate of EGP in NP females in the present 362 
study compared to its inhibitory actions in males published previously (25). Whether these 363 
differences are sex-linked or due to the differing ages and length of fasting remain unclear 364 
but insulin sensitivity is known to be greater in juvenile than adult animals and in adult 365 
women than men (35,36). In the present study, basal glucose production (Ra) was higher in 366 
pregnant than NP females as seen previously in dogs, sheep and women during late 367 
pregnancy (11,12,14). In mice, this is consistent with the greater total availability of hepatic 368 
glycogen associated with the increased relative size of the liver during pregnancy. 369 
Particularly at D16, EGP was activated readily and sustained for several hours.  Blood 370 
glucose concentrations were higher after fasting for 6 h than 3.5 h and could be increased 371 
above pre-treatment levels 2 h after initiating an acute hypoglycaemic challenge at D16 but 372 
not D19.    EGP were also significantly higher during hyperinsulinaemia in D16 dams than in 373 
the other two groups.  Since hepatic glycogen content and activity of glucose-6-phosphatase 374 
are similar at D16 and D19 (37), the results indicate that, in addition to differences in hepatic 375 
insulin sensitivity, there may also be a greater gluconeogenic capacity and/or a more robust 376 
counter-regulatory response to hypoglycaemia at D16 than D19. Mice may, therefore, appear 377 
to rely more heavily on glucose production to meet the glucose demands of the gravid uterus 378 
at D16 than D19. Although the causes of the changes in insulin sensitivity and glucose 379 
production with proximity to delivery remain unknown, they closely parallel gestational 380 
changes in maternal concentrations of corticosterone, a known insulin antagonist (4,37), with 381 
maximal values at D16 and progressively declining concentrations thereafter towards term 382 
(38). 383 
 384 
Fetal glucose utilisation tended to be less at D19 than D16, consistent with the changes in 385 
glucose metabolism seen in fetal sheep towards term (39). At D19, weight specific rates of 386 
glucose utilisation by the fetus (≈ 39 μmol/min/kg) and placenta (≈ 120 μmol/min/kg), 387 
estimated from their p2DG contents, were within the range of values reported previously for 388 
other species at ≥ 90% of gestation (40-42). Estimation of total feto-placental glucose 389 
utilization by the whole litter indicates that this increases by 15-20% between D16 and D19 390 
while total conceptus mass increases by 120%. Mouse pups must, therefore, be using 391 
nutrients other than glucose to sustain their growth rate during late gestation. Indeed, 392 
previous studies have shown that their growth is positively correlated to placental glucose 393 
transport at D16, but not at D19, and becomes progressively more dependent on placental 394 
amino acid transport towards term (43). A greater ATP requirement for active amino acid 395 
transport by the D19 placenta is consistent with its high rate of glucose utilization relative to 396 
other fetal and maternal tissues at this age. In addition, the lower maternal FFA and 397 
cholesterol concentrations during pregnancy indicate that lipids may also provide alternative 398 
substrates for feto-placental tissues during late gestation (44).  399 
 400 
In summary, the marked insulin resistance of glucose utilisation and production at D16 will 401 
favour fetal glucose acquisition when fetuses are entering their maximal growth phase (31). 402 
When the fetuses have nearly reached term weight and can use other substrates at D19, 403 
insulin sensitivity of maternal tissues like the liver improves, which will conserve 404 
proportionally more glucose for maternal use in anticipation of the imminent demands of 405 
labour and lactation. This late change in insulin-glucose dynamics is likely to be particularly 406 
important in mice in which the gravid uterus accounts for such a large proportion of maternal 407 
weight at term but may also have a significant role in the maternal metabolic preparations for 408 
delivery in other species when the primary site of maternal-offspring nutrient allocation 409 
switches from the uterus to the mammary gland. 410 
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FIGURE LEGENDS 577 
Figure 1. Mean ± SEM changes in blood glucose concentrations from basal pre-treatment 578 
values with time after intraperitoneal administration of (A) glucose (1 g/kg) and (B) insulin 579 
(0.25 U/kg) in non-pregnant (NP) females (n=8-11, open symbols) and pregnant dams at day 580 
(D)16 (n=6-9, grey symbols) and D19 (n=6-8, black symbols). Inserts show area (a) under the 581 
glucose curve (AUC) and (b) above the glucose curve (AAC). In (a) and (b), *significant 582 
increment above baseline values in each group (p<0.05, paired t-test). In (b) values at each 583 
sampling time with different letters indicate significant differences between groups (p<0.05, 584 
one way ANOVA).    585 
 586 
Figure 2. Mean ± SEM concentrations of (A) blood glucose and (B) plasma insulin in the 587 
basal (stippled columns) and hyperinsulinaemic (Stripped columns) periods of the 588 
hyperinsulinaemic-euglycaemic clamp, rates of glucose infusion (GIR), appearance (Ra) and 589 
disappearance (Rd) measured directly (C) or derived indirectly as differences in rates (D) 590 
from tritiated glucose infusion and the HEC protocol (whole body and hepatic insulin 591 
sensitivity and endogenous glucose production, EGP) in non-pregnant (NP) females (n=7, 592 
white columns) and pregnant dams at D16 (n=5, grey columns) and D19 (n=6, black 593 
columns). In (B) *significant difference in concentration from the basal period (p<0.01, 594 
paired t-test) while, within each period of the clamp, values with different superscripts are 595 
significantly different from each other (p<0.05, one-way ANOVA).  In (C) and (D) rates with 596 
different superscripts are significantly different from each other (p<0.05, one-way ANOVA). 597 
In (D) * significant difference between the values in the two states of the clamp (P<0.02, 598 
paired t-test).  599 
 600 
Figure 3. Mean ± SEM abundance of insulin signalling (a,b) and lipid metabolism (c,d) 601 
proteins in liver (A, C) and  skeletal muscle (B, D) of non-pregnant (NP) females (n=10, 602 
white columns) and pregnant dams at D16 (n=5, grey columns) and D19 (n=5-6, black 603 
columns). Values with different superscripts are significantly different from each other 604 
(p<0.05, one way ANOVA). *significant difference between D16 and D19 dams (p<0.05, t-605 
test). 606 
 607 
 608 
609 
610 
 611 
 612 
 613 
 614 
Table 1. List of primary antibodies used in this study. 
Primary antibody Manufacturer Dilution 
Insulin receptor (InsR) Santa Cruz, sc-711 1/400 
Insulin like growth factor receptor type 1 
IGF1R 
Santa Cruz, sc-713 1/400 
Catalytic subunits of phosphoinositide 3-
kinase (p110α/β) 
Cell Signalling, 4249, 
3011 
1/1000 
Regulatory subunits of phosphoinositide 
3-kinase (p85α) 
Millipore, 06-195 1/5000 in 1% 
milk 
Kinase Akt Cell Signalling, 9272 1/1000 
Phosphorylated (p)Akt Thr308 Cell Signalling, 9275 1/1000 
pAkt Ser473 Cell Signalling, 9271 1/1000 
Glycogen synthase kinase 3 (GSK3) Cell Signalling, 9315 1/1000 
pGSK3 Ser21/9 Cell Signalling, 9331 1/1000 
Ribosomal S6 kinase (S6K) Cell Signalling, 2708 1/1000 
pS6K Thr 389 Cell Signalling, 9234 1/1000 
Eukaryotic translocation initiation factor 4 
binding protein (4EBP) 
Cell Signalling, 9644 1/1000 
p4EBP Ser65 Cell Signalling, 9451 1/1000 
Mitogen activated protein kinase (MAPK) Cell Signalling, 4695 1/1000 
pMAPK Thr202/Tyr204 Cell Signalling, 4370 1/1000 
Lipoprotein lipase (LPL) Abcam, 21356 1/1000 
Sterol regulatory element binding protein 
(SREBP) 
Abcam, 3259 1/200 
Fatty acid synthase (FAS) Cell Signalling, 3180 1/1000 
Peroxisome proliferator – activated 
receptor alpha (PPARα) 
Abcam, 8934 1/1500 
Peroxisome proliferator – activated 
receptor gamma (PPARγ) 
Santa Cruz, sc-7273 1/200 
Fatty acid transport protein 1 (FATP1) Santa Cruz, sc-31955 1/400 
   
 
 
 
 
 
Table 2. The effect of pregnancy and gestational age on the biometry and biochemical 
composition in non-pregnant females and pregnant dams at day (D)16 and D19 of pregnancy. 
 Non-pregnant  Pregnant 
     D16    D19 
Biometry    
Total body weight BW (g) 
 
21.0 ± 0.4a (20) 31.0 ± 1.1b (13)     35.0 ± 1.2b (16) 
Hysterectomised weight  HW (g) 
 
-    24.0 ± 0.7b (13)     23.0 ± 0.8b (15) 
Liver (mg)   1099 ± 28a (10)  1903 ± 57b (13)   1856 ± 76b (16) 
(% )† 
 
    5.5 ± 0.2a (10)       7.9 ± 0.1b (13)       8.1 ± 0.3b (16) 
Kidney (mg)    234.0 ± 6.5a (10)  277 ± 12b (11) 271 ± 11b (15) 
(% )† 
 
1.20 ± 0.02 (10) 1.10 ± 0.02 (11) 1.20 ± 0.04 (15) 
Heart (mg) 106.0 ± 6.5a (10) 132 ± 5b (13) 137 ± 7b (16) 
(% )† 
 
0.50 ± 0.03 (10)   0.50 ± 0.01 (13) 0.60 ± 0.03 (16) 
Retroperitoneal fat (mg) 30 ± 2a (16) 73 ± 7b (13) 63 ± 6b (16) 
 (%)† 
 
0.1 ± 2.0a (16) 0.30 ± 0.03b (13)   0.30 ± 0.03b (16) 
Gravid uterus (g) - 7.3 ± 0.4 (13) 11.2 ± 0.7* (15) 
Placenta average per litter (mg) - 104.0 ± 1.8 (13) 88.0 ± 2.7* (16) 
Fetus average per litter (mg) -   427 ± 12 (13) 1204 ± 17* (16) 
Litter size - 7.8 ± 0.5 (13) 7.1 ± 0.4 (16) 
    
Biochemical composition    
DEXA absolute fat mass (g)†        3.9 ± 0.2 (10)        4.4 ± 0.3 (7)       4.5 ± 0.2 (7) 
DEXA fat mass (%)† 
 
17.6 ± 0.9 (10) 17.8 ± 1.2 (7)     19.2 ± 0.5 (7) 
DEXA absolute lean mass (g)† 18.2 ± 0.6a (10) 20.3 ± 0.5b (7)    18.7 ± 0.7ab (10) 
DEXA lean mass (%)† 
 
82.4 ± 0.9 (10) 82.3 ± 1.2 (7)     80.9 ± 0.5 (10) 
Hepatic glycogen (mg/g) 55 ± 3 (15)        49 ± 1 (6)       57 ± 6 (6) 
Total hepatic glycogen (mg)    61 ± 4a (15) 86 ± 3b (6)  103 ± 11b (6) 
Hepatic fat content (%) 5.4 ± 0.3 (15) 5.1 ± 0.3 (6)      4.7 ± 0.3 (6) 
Total hepatic fat content (mg) 
 
    59 ± 5a (15) 91 ± 6b (6)        86 ± 6b (6) 
Skeletal muscle fat content (%)§ 4.0 15.4 20.4 
    
    
Data are expressed as mean ± SEM with the number of dams/litters in parentheses. Values 
with different superscripts are significantly different from each other (p<0.05, one way 
ANOVA).  *significant difference between D16 and D19 pregnant dams (p<0.05, t-test). † 
Organ weights and DEXA results were expressed as % of total body weight for NP females 
and of hysterectomised for pregnant dams.   § skeletal muscle fat content was measured on 
samples pooled from 3-5 animals from each group. 
 
 
Table 3. The effect of pregnancy and gestational age on blood glucose concentrations in the 
fed and fasted state, plasma concentrations of free fatty acids (FFA), triglycerides (TG), 
cholesterol, insulin, leptin and insulin-like growth factor (IGF)1 in non-pregnant females and 
dams at day (D)16 and D19 of pregnancy in the fed state. 
 Non-pregnant Pregnant 
  D16 D19 
Glucose  Fed state (mmol/l) 9.3 ± 0.5 (10) 10.3 ± 0.3 (11) 9.4 ± 0.6 (16) 
               Fasted 3.5h (mmol/l) 7.1 ± 0.4a (8) 5.3 ± 0.3b (6) 5.5 ± 0.3b (6) 
               Fasted 6h (mmol/l) 
 
   6.9 ± 0.3a (11)  6.8 ± 0.2a† (9) 5.2 ± 0.3b (8) 
FFA  Fed (μmol/l) 
 
637 ± 49a (10) 256 ± 42b (9) 381 ± 41b*(10) 
TG    Fed (mmol/l) 
 
1.0 ± 0.1 (10) 1.2 ± 0.2 (9) 1.0 ± 0.1 (10) 
Cholesterol  Fed (mmol/l) 
 
1.8 ± 0.1a (10) 1.4 ± 0.1b (9) 1.0 ± 0.1c (10) 
Insulin         Fed (μg/L) 
 
0.19 ± 0.04a (10) 1.3 ± 0.3b (10) 0.6 ± 0.1ab (10) 
Leptin         Fed (pg/ml) 
 
766 ± 71a (10) 4058 ± 656b (10) 3927 ± 709b (10) 
IGF1           Fed (pg/ml) 487 ± 68a (10) 299 ± 23b (12) 253 ± 20b (12) 
    
Data are expressed as mean±SEM with the number of animals shown in parentheses. Values 
with different superscripts are significantly different from each other (p<0.05, one way 
ANOVA). The asterisk indicates a significant difference between D16 and D19 of pregnancy 
(p<0.05, t-test).  † indicates a significantly different values between animals fasted for 3.5h 
and 6h in the same group.  
 
 
 
 
 
 
 
 
 
 
Table 4. Glucose utilisation by skeletal muscle and adipose tissue of the adult non-pregnant 
and pregnant mice and by the feto-placental tissues of the pregnant dams at day (D)16 and 
D19 of pregnancy. 
p2DG content (nmol/mg) Non-pregnant Pregnant 
  D16 D19 
Skeletal muscle 6.8 ± 2.4   4.2 ± 2.1   2.0 ± 0.6 
White adipose tissue 3.2 ± 1.3   1.3 ± 0.3   1.3 ± 0.8 
Placenta             - 4.8 ± 1.9 5.4 ± 1.2† 
Fetus             - 3.5 ± 1.8 1.7 ± 0.3 
    
Data are expressed as mean ± SEM for non-pregnant females (n=7) and pregnant dams/litters 
(D16 n=5, D19 n=6 with 2 conceptuses per litter). † Significantly different from the other 
tissues at this stage of pregnancy (p<0.01, one-way ANOVA). 
 
